Amplification of the epidermal growth factor receptor (EGFR) is the commonest genetic aberration, occurring in about 50% of de novo primary GBMs, half of which harbor the EGFRvIII mutation (in‐frame deletion of exons 2–7) leading to constitutive and ligand‐independent receptor activity.17 Thus, there is a strong rationale to develop an EGFR‐targeted PIT strategy, guided by functional molecular imaging, which could significantly improve GBM patient management. Here, EGFR is linked to glioblastoma.